Truvada is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV\-1\), a virus that causes acquired immune deficiency syndrome (AIDS). In addition it may be used from the age of 12 in adolescents with HIV who are resistant to first\-line treatments or who cannot take them because of side effects. Truvada is also used to help prevent sexually transmitted HIV\-1 infection in adults and adolescents who are at high risk of being infected (pre\-exposure prophylaxis or PrEP). It should be used in combination with safer sex practices, such as use of condoms. Truvada contains two active substances, emtricitabine (200 mg) and tenofovir disoproxil (245 mg).
Therapeutic Indication
Treatment of HIV\-1 infection: * Truvada is indicated in antiretroviral combination therapy for the treatment of HIV\-1 infected adults. * Truvada is also indicated for the treatment of HIV\-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to \< 18 years. Pre\-exposure prophylaxis (PrEP): * Truvada is indicated in combination with safer sex practices for pre\-exposure prophylaxis to reduce the risk of sexually acquired HIV\-1 infection in adults at high risk.
Therapeutic Area (MeSH)
ATC Code
J05AR03
ATC Item
N/A
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| emtricitabine | N/A | emtricitabine |
| tenofovir disoproxil fumarate | N/A | tenofovir disoproxil fumarate |
EMA Name
Truvada
Medicine Name
Truvada
Aliases
N/ANo risk management plan link.
